A Versatile Technology.
A Veteran Team.

Addressing unmet needs in oncology.

Watch Video
Ending Cancer Drug Resistance

Our Company

Bold Therapeutics is a clinical-stage pharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company’s lead asset is BOLD-100, a first-in-class ruthenium-based small molecule therapeutic with applications in both oncology and infectious disease.

Watch a presentation.

Introducing BOLD-100

Bold Therapeutics' development strategy focuses on some of the most challenging cancer indications where existing therapies are largely ineffective, and where BOLD-100 can have the largest impact on patient outcomes. BOLD-100 has a unique mechanism-of-action that is optimal for targeting hard-to-treat cancers. Preclinical and clinical development has demonstrated the potential of BOLD-100 in a wide range of cancer indications and drug combinations. Learn More


BOLD-100 Clinical Development

BOLD-100 is the most clinically advanced ruthenium-based therapeutics currently in development. BOLD-100 is currently in a Phase 2 clinical trial in combination with FOLFOX for the treatment of advanced gastric, pancreatic, colon and bile duct cancers (NCT04421820). A previously completed Phase 1b trial indicated that BOLD-100 can be safely combined with FOLFOX chemotherapy, with no new Grade 3 or 4 treatment-emergent adverse events; and patients can safely remain on treatment for an extended number of treatment cycles. Learn More

Learn More